SillaJen Inc Total Liabilities

Latest as of September 2025: ₩6.58 Billion KRW ≈ $4.46 Million USD

SillaJen Inc total liabilities. Based on the latest financial reports, SillaJen Inc (215600) has total liabilities worth ₩6.58 Billion KRW (≈ $4.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SillaJen Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of SillaJen Inc (2015–2024)

Total liabilities of SillaJen Inc from 2015 to 2024. This chart illustrates how SillaJen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of SillaJen Inc to see how much of total assets are deployed in long-term investments.

SillaJen Inc Competitors by Total Liabilities

The table below lists competitors of SillaJen Inc ranked by their total liabilities.

Company Country Total Liabilities
Gulf Island Fabrication Inc
NASDAQ:GIFI
USA $52.42 Million
SOL-GEL TECHN. IS-10
F:4SG
Germany €5.66 Million
Sagar Cements Limited
NSE:SAGCEM
India Rs26.38 Billion
Eureka Group Holdings Ltd
AU:EGH
Australia AU$152.71 Million
Tcc Steel
KO:002710
Korea ₩326.43 Billion
Dream Office Real Estate Investment Trust
TO:D-UN
Canada CA$1.32 Billion
ANGI Homeservices Inc
NASDAQ:ANGI
USA $637.85 Million
Alx Oncology Holdings 
NASDAQ:ALXO
USA $24.63 Million

Liability Composition Analysis (2015–2024)

This chart breaks down SillaJen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SillaJen Inc total assets.

Liquidity & Leverage Metrics

SillaJen Inc Total Liabilities Ratios Explained

SillaJen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 18.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SillaJen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SillaJen Inc (2015–2024)

The table below shows the annual total liabilities of SillaJen Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩17.20 Billion
≈ $11.66 Million
-11.35%
2023-12-31 ₩19.40 Billion
≈ $13.15 Million
-20.83%
2022-12-31 ₩24.51 Billion
≈ $16.61 Million
-8.49%
2021-12-31 ₩26.78 Billion
≈ $18.15 Million
+9.11%
2020-12-31 ₩24.54 Billion
≈ $16.63 Million
-12.67%
2018-12-31 ₩28.11 Billion
≈ $19.05 Million
-14.85%
2017-12-31 ₩33.01 Billion
≈ $22.37 Million
-56.66%
2016-12-31 ₩76.16 Billion
≈ $51.61 Million
+15.23%
2015-12-31 ₩66.09 Billion
≈ $44.79 Million
--

About SillaJen Inc

KQ:215600 Korea Biotechnology
Market Cap
$188.15 Million
₩277.64 Billion KRW
Market Cap Rank
#16578 Global
#616 in Korea
Share Price
₩2010.00
Change (1 day)
+1.82%
52-Week Range
₩1844.00 - ₩4975.00
All Time High
₩121250.15
About

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more